OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence
Daniel Kreatsoulas, Chelsea Bolyard, Bill X. Wu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 49
Daniel Kreatsoulas, Chelsea Bolyard, Bill X. Wu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 49
Showing 1-25 of 49 citing articles:
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives
Hao Lin, Chaxian Liu, An-Kang Hu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 62
Hao Lin, Chaxian Liu, An-Kang Hu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 62
Immunotherapy for glioblastoma: current state, challenges, and future perspectives
Yang Liu, Zhou Fei, Heba Ali, et al.
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 12, pp. 1354-1375
Open Access | Times Cited: 22
Yang Liu, Zhou Fei, Heba Ali, et al.
Cellular and Molecular Immunology (2024) Vol. 21, Iss. 12, pp. 1354-1375
Open Access | Times Cited: 22
Applications of polymeric nanoparticles in drug delivery for glioblastoma
Shuhan Liu, Bin Tan, Feng Wang, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access | Times Cited: 2
Shuhan Liu, Bin Tan, Feng Wang, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access | Times Cited: 2
Cathepsin B-Responsive Programmed Brain Targeted Delivery System for Chemo-Immunotherapy Combination Therapy of Glioblastoma
Shaoping Jiang, Wenpei Li, Jun Yang, et al.
ACS Nano (2024) Vol. 18, Iss. 8, pp. 6445-6462
Closed Access | Times Cited: 13
Shaoping Jiang, Wenpei Li, Jun Yang, et al.
ACS Nano (2024) Vol. 18, Iss. 8, pp. 6445-6462
Closed Access | Times Cited: 13
The Importance of M1-and M2-Polarized Macrophages in Glioma and as Potential Treatment Targets
Jiangbin Ren, Bangjie Xu, Jianghao Ren, et al.
Brain Sciences (2023) Vol. 13, Iss. 9, pp. 1269-1269
Open Access | Times Cited: 22
Jiangbin Ren, Bangjie Xu, Jianghao Ren, et al.
Brain Sciences (2023) Vol. 13, Iss. 9, pp. 1269-1269
Open Access | Times Cited: 22
Crosstalk between microglia and neural stem cells influences the relapse of glioblastoma in GBM immunological microenvironment
Xingliang Dai, Lei Ye, Huaixu Li, et al.
Clinical Immunology (2023) Vol. 251, pp. 109333-109333
Closed Access | Times Cited: 18
Xingliang Dai, Lei Ye, Huaixu Li, et al.
Clinical Immunology (2023) Vol. 251, pp. 109333-109333
Closed Access | Times Cited: 18
Laser‐Activatable In Situ Vaccine Enhances Cancer‐Immunity Cycle
Zhenyu Wang, Tingting You, Qianyi Su, et al.
Advanced Materials (2023) Vol. 35, Iss. 52
Closed Access | Times Cited: 18
Zhenyu Wang, Tingting You, Qianyi Su, et al.
Advanced Materials (2023) Vol. 35, Iss. 52
Closed Access | Times Cited: 18
Personalised therapeutic approaches to glioblastoma: A systematic review
Oliver Mowforth, Jamie Brannigan, Marc El Khoury, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 16
Oliver Mowforth, Jamie Brannigan, Marc El Khoury, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 16
Crosstalk between glioblastoma and tumor microenvironment drives proneural–mesenchymal transition through ligand-receptor interactions
Yancheng Lai, Xiaole Lu, Yankai Liao, et al.
Genes & Diseases (2023) Vol. 11, Iss. 2, pp. 874-889
Open Access | Times Cited: 15
Yancheng Lai, Xiaole Lu, Yankai Liao, et al.
Genes & Diseases (2023) Vol. 11, Iss. 2, pp. 874-889
Open Access | Times Cited: 15
A scientometric analysis and up-to-date review of nano-based drug delivery systems in glioblastoma treatment
Xing Yang, Feroza Yasinjan, Mei Yang, et al.
Nano Today (2023) Vol. 52, pp. 101961-101961
Closed Access | Times Cited: 13
Xing Yang, Feroza Yasinjan, Mei Yang, et al.
Nano Today (2023) Vol. 52, pp. 101961-101961
Closed Access | Times Cited: 13
Glioma-derived ANXA1 suppresses the immune response to TLR3 ligands by promoting an anti-inflammatory tumor microenvironment
Yu Zheng, Haihui Jiang, Naixue Yang, et al.
Cellular and Molecular Immunology (2023) Vol. 21, Iss. 1, pp. 47-59
Closed Access | Times Cited: 11
Yu Zheng, Haihui Jiang, Naixue Yang, et al.
Cellular and Molecular Immunology (2023) Vol. 21, Iss. 1, pp. 47-59
Closed Access | Times Cited: 11
Small Molecule Immunomodulators as Next-Generation Therapeutics for Glioblastoma
Somaya A. Abdel‐Rahman, Moustafa T. Gabr
Cancers (2024) Vol. 16, Iss. 2, pp. 435-435
Open Access | Times Cited: 4
Somaya A. Abdel‐Rahman, Moustafa T. Gabr
Cancers (2024) Vol. 16, Iss. 2, pp. 435-435
Open Access | Times Cited: 4
Comprehensive machine learning-based integration develops a novel prognostic model for glioblastoma
Qian Jiang, Xiawei Yang, Teng Deng, et al.
Deleted Journal (2024) Vol. 32, Iss. 3, pp. 200838-200838
Open Access | Times Cited: 4
Qian Jiang, Xiawei Yang, Teng Deng, et al.
Deleted Journal (2024) Vol. 32, Iss. 3, pp. 200838-200838
Open Access | Times Cited: 4
Comprehensive Analysis of GPSM2 : From Pan‐Cancer Analysis to Experimental Validation
Chunjiao Yang, Yuzhe Zhang, Lirong Yan, et al.
Journal of Cellular and Molecular Medicine (2025) Vol. 29, Iss. 7
Open Access
Chunjiao Yang, Yuzhe Zhang, Lirong Yan, et al.
Journal of Cellular and Molecular Medicine (2025) Vol. 29, Iss. 7
Open Access
Warburg effect‐related risk scoring model to assess clinical significance and immunity characteristics of glioblastoma
Rong Zhang, Can Wang, Xiaohong Zheng, et al.
Cancer Medicine (2023) Vol. 12, Iss. 21, pp. 20639-20654
Open Access | Times Cited: 10
Rong Zhang, Can Wang, Xiaohong Zheng, et al.
Cancer Medicine (2023) Vol. 12, Iss. 21, pp. 20639-20654
Open Access | Times Cited: 10
Radiogenomic biomarkers for immunotherapy in glioblastoma: A systematic review of magnetic resonance imaging studies
Prajwal Ghimire, Ben Kinnersley, Golestan Karami, et al.
Neuro-Oncology Advances (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 3
Prajwal Ghimire, Ben Kinnersley, Golestan Karami, et al.
Neuro-Oncology Advances (2024) Vol. 6, Iss. 1
Open Access | Times Cited: 3
A multidimensional pan‐cancer analysis of DCAF13 and its protumorigenic effect in lung adenocarcinoma
Shan Wei, Kaining Lu, Jing Xing, et al.
The FASEB Journal (2023) Vol. 37, Iss. 4
Open Access | Times Cited: 8
Shan Wei, Kaining Lu, Jing Xing, et al.
The FASEB Journal (2023) Vol. 37, Iss. 4
Open Access | Times Cited: 8
Unravelling the Glioblastoma Tumour Microenvironment: Can Aptamer Targeted Delivery Become Successful in Treating Brain Cancers?
Breanna Giles, Maryam Nakhjavani, Andrew Wiesa, et al.
Cancers (2023) Vol. 15, Iss. 17, pp. 4376-4376
Open Access | Times Cited: 8
Breanna Giles, Maryam Nakhjavani, Andrew Wiesa, et al.
Cancers (2023) Vol. 15, Iss. 17, pp. 4376-4376
Open Access | Times Cited: 8
Case report: Temozolomide induced hypermutation indicates an unfavorable response to immunotherapy in patient with gliomas
Jiapeng Liu, Shuli Hu, Haihui Jiang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Jiapeng Liu, Shuli Hu, Haihui Jiang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
GBM Immunotherapy: Macrophage Impacts
Nina Loginova, Denis Aniskin, Peter Timashev, et al.
Immunological Investigations (2024) Vol. 53, Iss. 5, pp. 730-751
Closed Access | Times Cited: 2
Nina Loginova, Denis Aniskin, Peter Timashev, et al.
Immunological Investigations (2024) Vol. 53, Iss. 5, pp. 730-751
Closed Access | Times Cited: 2
Radiation-primed TGF-β trapping by engineered extracellular vesicles for targeted glioblastoma therapy
Ruyu Liang, Hongyu Lu, Haifeng Zhu, et al.
Journal of Controlled Release (2024) Vol. 370, pp. 821-834
Closed Access | Times Cited: 2
Ruyu Liang, Hongyu Lu, Haifeng Zhu, et al.
Journal of Controlled Release (2024) Vol. 370, pp. 821-834
Closed Access | Times Cited: 2
Microfluidic-Derived Docosahexaenoic Acid Liposomes for Targeting Glioblastoma and Its Inflammatory Microenvironment
Daniel Mendanha, Marta R. Casanova, Sara Gimondi, et al.
ACS Applied Materials & Interfaces (2024) Vol. 16, Iss. 31, pp. 40543-40554
Open Access | Times Cited: 2
Daniel Mendanha, Marta R. Casanova, Sara Gimondi, et al.
ACS Applied Materials & Interfaces (2024) Vol. 16, Iss. 31, pp. 40543-40554
Open Access | Times Cited: 2
Insights of immune cell heterogeneity, tumor-initiated subtype transformation, drug resistance, treatment and detecting technologies in glioma microenvironment
Tongzheng Chen, Wenbin Ma, Xin Wang, et al.
Journal of Advanced Research (2024)
Open Access | Times Cited: 2
Tongzheng Chen, Wenbin Ma, Xin Wang, et al.
Journal of Advanced Research (2024)
Open Access | Times Cited: 2
Type I interferon signaling regulates myeloid and T cell crosstalk in the glioblastoma tumor microenvironment
Juhee Lim, Jeongwoo La, Hyeon Cheol Kim, et al.
iScience (2024) Vol. 27, Iss. 9, pp. 110810-110810
Open Access | Times Cited: 2
Juhee Lim, Jeongwoo La, Hyeon Cheol Kim, et al.
iScience (2024) Vol. 27, Iss. 9, pp. 110810-110810
Open Access | Times Cited: 2
Therapeutic Potential of Nanomedicine in Management of Alzheimer’s Disease and Glioma
Firoz Anwar, Fahad A. Al‐Abbasi, Salma Naqvi, et al.
International Journal of Nanomedicine (2023) Vol. Volume 18, pp. 2737-2756
Open Access | Times Cited: 5
Firoz Anwar, Fahad A. Al‐Abbasi, Salma Naqvi, et al.
International Journal of Nanomedicine (2023) Vol. Volume 18, pp. 2737-2756
Open Access | Times Cited: 5
